These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9366927)

  • 21. The influence of the immunosuppressants OKT3 and ATG on immunological parameters.
    Neumann MC; Müller TF; Sprenger H; Gemsa D; Lange H
    Clin Nephrol; 1996 May; 45(5):345-8. PubMed ID: 8738669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients.
    Fukuuchi F; Lefrançois N; Chapuis F; Gebuhrer L; Bosshard S; Dubernard JM; Touraine JL
    Transplant Proc; 1996 Oct; 28(5):2808-9. PubMed ID: 8908070
    [No Abstract]   [Full Text] [Related]  

  • 23. Quadruple-drug induction therapy in combined renal and pancreatic transplantation--OKT3 versus ATG.
    Illner WD; Theodorakis J; Abendroth D; Schleibner S; Stangl M; Landgraf R; Land W
    Transplant Proc; 1990 Aug; 22(4):1586-7. PubMed ID: 2117795
    [No Abstract]   [Full Text] [Related]  

  • 24. Influence of multiple factors (age, transplant number, recipient category, donor source) on outcome of pancreas transplantation at one institution.
    Gruessner A; Gruessner R; Moudry-Munns K; Dunn D; Najarian JS; Sutherland DE
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1303-5. PubMed ID: 8442121
    [No Abstract]   [Full Text] [Related]  

  • 25. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results.
    Baldi A; Malaise J; Mourad M; Squifflet JP
    Transplant Proc; 2000 Mar; 32(2):429-31. PubMed ID: 10715467
    [No Abstract]   [Full Text] [Related]  

  • 26. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
    Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P
    Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279
    [No Abstract]   [Full Text] [Related]  

  • 27. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunosuppressive requirements for small bowel/liver transplantation.
    McAlister V; Grant D; Wall W; Roy A; Ghent C; Zhong R; Duff J
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1204-5. PubMed ID: 8442086
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of steroid resistant acute rejection after renal transplantation.
    Oh CK; Kim YS; Kim MS; Kim SI; Park K
    Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
    [No Abstract]   [Full Text] [Related]  

  • 30. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
    Alamartine E; Bellakoul R; Berthoux F
    Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of antilymphocyte induction therapy in liver transplantation: A European perspective.
    Langrehr JM; Neuhaus PJ
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S71-84. PubMed ID: 10431020
    [No Abstract]   [Full Text] [Related]  

  • 32. Graft outcome in patients with biopsy-proven chronic renal allograft rejection.
    Peddi VR; Schroeder TJ; Weiskittel P; First MR
    Transplant Proc; 1999; 31(1-2):1308-9. PubMed ID: 10083584
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful pancreas-renal transplantation without anti-T-cell antibody induction.
    Shapiro ME; Abrams JM; Brown RS; Steinman TI; Strom TB
    Transplant Proc; 1995 Dec; 27(6):3087-8. PubMed ID: 8539857
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunosuppression is not related to the response to steroids in acute liver rejection.
    Bercedo J; Jiménez C; Moreno E; García MA; Palomo JC; Loinaz C; Marcello M; Moreno C; Chamorro A; Manzanera M
    Transplant Proc; 1995 Aug; 27(4):2328-9. PubMed ID: 7652830
    [No Abstract]   [Full Text] [Related]  

  • 35. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
    Laske A; Gallino A; Schneider J; Bauer EP; Carrel T; Pasic M; von Segesser LK; Turina MI
    J Heart Lung Transplant; 1992; 11(3 Pt 1):557-63. PubMed ID: 1610864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection.
    Gaber LW; Moore LW; Alloway RR; Flax S; Gaber AO
    Transplant Proc; 1995 Feb; 27(1):1019. PubMed ID: 7878784
    [No Abstract]   [Full Text] [Related]  

  • 37. FK 506-based immunosuppression in clinical pancreas transplantation.
    Swanson C; Rubin M; Colquhoun S; Basadonna G; Asshinnik A; Perez R
    Transplant Proc; 1995 Dec; 27(6):3031. PubMed ID: 8539827
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 39. Experience with azathioprine withdrawal after simultaneous kidney-pancreas transplantation.
    Stratta RJ
    Transplant Proc; 1998 Jun; 30(4):1353-4. PubMed ID: 9636550
    [No Abstract]   [Full Text] [Related]  

  • 40. Muromonab-CD3 and antithymocyte globulin in renal transplantation.
    Burk ML; Matuszewski KA
    Ann Pharmacother; 1997 Nov; 31(11):1370-7. PubMed ID: 9391693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.